Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population
Xiang Li(Bioscience (China)), Ting-Bo Liang(Second Affiliated Hospital of Zhejiang University), Risheng Que(Second Affiliated Hospital of Zhejiang University), Lei Zheng(Fujian Medical University), Qi Zhang(Second Affiliated Hospital of Zhejiang University), Tao Ma(Southwest Forestry University), Yun Zhang(Janssen (Belgium)), Ri-Sheng Yu(Second Affiliated Hospital of Zhejiang University), Qi-Chun Wei(Second Affiliated Hospital of Zhejiang University), Xue-Li Bai(Second Affiliated Hospital of Zhejiang University), Cheng-Xiang Guo(Second Affiliated Hospital of Zhejiang University), Shu-Mei Wei(Second Affiliated Hospital of Zhejiang University), Jian-Ying Lou(Second Affiliated Hospital of Zhejiang University), Shun-Liang Gao(Second Affiliated Hospital of Zhejiang University), Yi-Nan Shen(Second Affiliated Hospital of Zhejiang University), Pei-Wei Sun(Second Affiliated Hospital of Zhejiang University), Guo-Gang Li(Second Affiliated Hospital of Zhejiang University), Yi-gang Chen(Second Affiliated Hospital of Zhejiang University), Ying Yuan(Zhejiang Cancer Hospital)
Cited by 62
Related Papers
Regulatory T cells in cardiovascular diseases
|Nature Reviews Cardiology|2015|410
Plastome phylogeny and early diversification of Brassicaceae
|BMC Genomics|2017|211
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
|The Lancet Oncology|2020|193